Skip to main content
Free shipping on all orders
888-559-3802
Shop
Learn
For Practitioners
At-Home Lab Testing
VitabaseGPT
Specials
Go back
VitabaseIngredients

Inositol phosphate

Table of contents

Other Names

(1R,2S,3r,4R,5S,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexakis(phosphate)1D-myo-inositol 4-phosphate1D-myo-inositol 5-phosphate1D-myo-inositol 6-phosphate1D-myo-inositol hexakisphosphateDiphosphoryl inositol phosphateInositol 1,3,4,5-tetrakisphosphateInositol 1,4-bisphosphateInositol bisphosphateInositol hexakisphosphateInositol hexaphosphateInositol hexaphosphoric acidInositol monophosphateInositol polyphosphateInositol pyrophosphateInositol tetrakisphosphateInositol trisphosphateIns(1,4,5)P3InsP6IP1IP2IP3IP4IP6myo-Inositol 1,4,5-trisphosphatemyo-Inositol 1-phosphatemyo-Inositol 2-phosphatemyo-Inositol hexakis(dihydrogen phosphate)myo-Inositol hexakisphosphatemyo-Inositol hexaphosphatePhosphoinositidePhytatePhytic acidPhytinPP-IP

Synopsis

Inositol Phosphate (Phytic Acid / IP6): A Comprehensive Reference

1. Identity: Chemical Names, Molecular Characteristics, and Natural Sources

1.1 Nomenclature and Chemical Identity

Phytic acid is a six-fold dihydrogenphosphate ester of inositol (specifically, of the myo isomer), also called inositol hexaphosphate, inositol hexakisphosphate (IP6), or inositol polyphosphate. It is a fully saturated cyclic acid and phosphate ester of inositol, having the chemical formula C6H18O24P6. The compound possesses the trivial names of inositol hexakisphosphate (IP6, InsP6) or phytic acid, with the last one commonly used. Its CAS number is 83-86-3.

At physiological pH, the phosphates are partially ionized, resulting in the phytate anion. The (myo) phytate anion is a colorless species that has a significant nutritional role as the principal storage form of phosphorus in many plant tissues, especially bran and seeds. Due to its six phosphate groups, IP6 possesses a high density of negative charges that partially ionize at physiological pH.

The lower inositol polyphosphates are inositol esters with less than six phosphates, such as inositol penta- (IP5), tetra- (IP4), and triphosphate (IP3). These occur in nature as catabolites of phytic acid. Phytases promote IP6 dephosphorylation into smaller inositol phosphates (IP1–IP5), also belonging to the phytates family.

Phytic acid isolated from plants belongs to the group of organic phosphates and is a mixture of calcium–magnesium salt of inositol hexaphosphoric acid, also known as phytin. Salts of phytic acid are also called phytate.

1.2 Natural Sources and Plant Distribution

Phytates can be found in numerous plants and their parts, including seeds, nuts, legumes, and cereals. Phytic acid is primarily present in edible cereals, particularly in seeds, where it makes up 50%–85% of the total phosphorus content. It is abundant in various plant-based foods, serving as a primary storage form of phosphorus. It is particularly concentrated in the bran and seeds of many plants, typically ranging from 0.5% to 3% of their dry weight.

Common dietary sources rich in IP6 include whole grains like wheat, rice, corn, and oats. Legumes such as soybeans, beans, peas, and lentils also contain substantial quantities. Seeds (including linseed and sunflower seeds) and nuts are notable sources as well. Some forms of inositol (i.e., inositol phosphates, lipid-bound inositol, free inositol) are naturally found in many foods including unprocessed whole grains, nuts, cantaloupe, citrus fruits, lima beans, chickpeas, lentils, raisins, and cabbage.

Phytic acid is a natural plant inositol hexaphosphate comprising up to 10–30 g/kg dry matter in nuts, cereals, edible legumes, and oil seeds.

1.3 Endogenous Presence in Mammals

In addition to being found in plants, IP6 is contained in almost all mammalian cells, although in much smaller amounts, where it is important in regulating vital cellular functions such as signal transduction, cell proliferation, and differentiation. It is also present in mammalian cells and tissues at concentrations in the μM range. Its presence in human tissues and body fluids was only confirmed at the end of the 1990s, after the development of sensitive assay methods. In 1996, IP6 levels were shown to be present in human urine, and this led to the establishment of a link between IP6 and health, particularly with respect to calcium-related diseases, such as renal stones, osteoporosis, and cardiovascular calcification.

1.4 Common Supplement Forms and Preparations

Most supplement products list "inositol hexaphosphate," "IP6," or "phytic acid," often combined with myo-inositol. Capsule strengths typically range from 250 mg to 1,000 mg of IP6 per serving. IP6 is also available as a powder and in combined preparations with free myo-inositol, a formulation that has been specifically employed in clinical research. A pharmaceutical-grade intravenous formulation exists as well: SNF472, which is a hexasodium salt of the active ingredient, myo-inositol hexaphosphate (IP6), or phytate, developed for clinical applications distinct from over-the-counter dietary supplements.

The calcium salt of IP6 is listed by the Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). Phytate is also classified by the FDA as Generally Recognized As Safe (GRAS).

2. Historical Discovery and Use

2.1 Scientific Discovery

Phytates were first discovered in 1855 by a German researcher Theodor Hartig, who identified circular particles in different plant seeds. The chemical structure of phytate was later defined in 1914 as myo-inositol-1,2,3,4,5,6-hexakis dihydrogen phosphate.

Although this molecule was discovered in 1855, its biological effects as an antinutrient were first described in 1940. The antinutrient effect of phytate results because it can decrease the bioavailability of important minerals under certain circumstances.

During the past 30 years, researchers have identified many important health benefits of phytate. Thus, 150 years elapsed since the discovery of phytate to the first descriptions of its beneficial effects. This long delay may be due to the difficulty in determining phytate in biological media, and because phytate dephosphorylation generates many derivatives (InsPs) that also have important biological functions.

2.2 Traditional Dietary Context

Inositol phosphate has no documented history as a deliberately extracted or purposively administered traditional medicine in any named ethnomedicinal tradition. Its traditional "use" is inherent in the historical human diet: populations consuming diets rich in whole grains, legumes, and seeds have always ingested phytate as an integral food component. Phytate is a major component of the Mediterranean and Dietary Approaches to Stop Hypertension (DASH) diets. The Mediterranean diet provides 1 g to 1.5 g of daily phytate as a calcium/magnesium salt (also known as phytin), much more than diets with refined cereals. The European/American diet can supply a broad range of 0.2 g to 1.5 g of daily phytate, depending on consumption of legumes, nuts, and whole cereals.

Traditional food preparation methods such as soaking, fermenting, and sprouting were practiced across many cultures precisely to enhance digestibility of grains and legumes. Phytases promote IP6 dephosphorylation into smaller inositol phosphates (IP1–IP5); complexed cations and proteins are also released when phytases cleave the phosphate groups from the phytate, enhancing their bioaccessibility. These preparation methods effectively reduce phytate content, although the use of such methods was motivated by palatability and digestibility rather than specific knowledge of phytic acid chemistry.

Investigations from the mid-20th century, such as those by McCance and Widdowson (1942), observed that diets rich in phytate notably reduced mineral bioavailability, and this contributed to decades of negative framing before the compound's health-promoting properties began to be characterized. At the 1936 meeting of the American Chemical Society, professor Edward Bartow of the University of Iowa presented a commercially viable means of extracting large amounts of inositol from the phytic acid naturally present in waste corn.

3. Key Constituents and Mechanisms of Action

3.1 The Inositol Phosphate Family

Other inositol phosphates, such as inositol pentaphosphates (InsP5s) and inositol tetraphosphates (InsP4s), occur at lower levels in plant foods (less than 15% of all InsPs). It has also been demonstrated that the ingestion of phytate generates other inositol phosphates (InsP5, InsP4, InsP3, InsP2), which can also play an important role in pathological conditions. Phytic acid is a [PO4]3− storage depot and precursor for other inositol phosphates and pyrophosphates.

3.2 Mineral Chelation

Phytic acid and phytate have a strong binding affinity to the dietary minerals calcium, iron, and zinc, inhibiting their absorption in the small intestine. This chelation depends on the proportion of phytate to metal and the pH. The ideal molar ratio of phytate to iron is around 0.4, while those above 1 can limit iron absorption. For zinc, ratios higher than 15 impede bioavailability, and those below 5 are best.

The use of phytate as an antioxidant has been related to its ability to chelate with iron and remove it from circulation. In this process, iron-hydroxyl radical formation and the suppression of iron-catalyzed lipid peroxidation would be blocked.

3.3 Antioxidant Mechanism

Phytate is a natural antioxidant, mainly acting to inhibit free radicals by preventing the Fenton reaction, or oxidative reactions involving iron that produce potentially damaging free radicals and oxidative species. This molecular arrangement enables a high-affinity interaction with iron, effectively blocking its catalytic role in hydroxyl radical formation and thereby fortifying IP6's antioxidant capacity. Lower inositol phosphates can act as antioxidants by inhibiting iron-mediated oxidative reactions, enhancing immunity by increasing Natural Killer cell function and activity, and stimulating bacterial killing by neutrophils.

3.4 Crystallization Inhibition

IP6 can bind to the growth sites of hydroxy-apatite (HA) and calcium oxalate crystals to prevent their growth and hence inhibit pathological calcification. In vitro studies have shown that InsP6 and its hydrolysates (InsPs), as well as pyrophosphate, bisphosphonates, and other polyphosphates, have high capacity to inhibit calcium salt crystallization. SNF472 inhibits the development and progression of calcification by binding to growth sites of hydroxyapatite crystal; this mechanism appears to be agnostic to the underlying cause of calcification.

3.5 Intracellular Signaling

Exogenously administered IP6 is rapidly taken up into cells and dephosphorylated to lower inositol phosphates, which further affect signal transduction pathways resulting in cell cycle arrest. Metabolites and derivatives of IP6 perform secondary messenger roles, including mobilization of intracellular calcium for mitosis. Extracellular signaling has also been demonstrated. IP6 interacts with both tyrosine kinase and PLC-coupled growth factor receptors. IP6 also enters the inositol phosphates pool, is subsequently dephosphorylated, and contributes to additional cellular signal transduction and intracellular functions.

In one important family of pathways, phosphatidylinositol 4,5-bisphosphate (PIP2) is stored in cellular membranes until it is released by any of a number of signalling proteins and transformed into various secondary messengers, for example diacylglycerol and inositol trisphosphate.

3.6 Cell Cycle and Apoptotic Mechanisms

In vitro and animal studies suggest that IP6 reduces initiation and/or promotion, inhibits proliferation by chelation of metalloproteins, causes G0/G1 arrest, and induces differentiation of various cancer cell lines. IP6 treatment of cells resulted in a strong growth inhibition and an increase in G1 cell population. In mechanistic studies, IP6 resulted in an increase in cyclin-dependent kinase inhibitors (CDKIs) Cip1/p21 and Kip1/p27 levels, together with a decrease in cyclin-dependent kinase (CDK) 4 and cyclin D1 protein levels.

IP6 inhibited proliferation and stimulated apoptosis of colon cancer cells. This effect was mediated by an increase in the expression of genes encoding p21, p27, caspase 3, caspase 9, as well as a decrease in transcription of AKT1 and S6K1. InsP6 suppressed phosphorylation of AKT1 and p70S6K1, a downstream effector of mTOR.

In addition to reducing cell proliferation, IP6 also induces differentiation of malignant cells. Enhanced immunity and antioxidant properties also contribute to tumor cell destruction.

3.7 Absorption and Metabolism

IP6 is highly polar and poorly absorbed when given orally. While IP6 provides natural protection against cardiovascular calcification related to aging, it is not absorbed well from dietary sources, and parenteral administration is required to achieve supraphysiologic levels with a potential to prevent or attenuate progression of cardiovascular calcification. Studies have shown that IP6 is rather rapidly absorbed by rats in vivo. Ion exchange chromatography demonstrates the presence of inositol and IP1–6 in gastric epithelial cells as early as within 1 hour of intragastric ³H-IP6 administration. The metabolized IP6, in the form of inositol and IP1, is transported via plasma and reaches distant organs as well as tumors. In rats, the urinary metabolites of IP6 are inositol and IP1.

InsP6 is well absorbed from the gastrointestinal tract and cellularly internalized through pinocytosis and endocytosis. In cells, it is partially dephosphorylated to its lower phosphorylated forms (InsP1–5), which enter the pool of inositol phosphates.

4. Scientific Evidence by Area of Health Application

4.1 Cancer Prevention and Oncology Support

Preclinical Evidence

Inositol hexaphosphate is a naturally occurring polyphosphorylated carbohydrate, abundantly present in many plant sources and in certain high-fiber diets. In addition to being found in plants, IP6 is contained in almost all mammalian cells, where it is important in regulating vital cellular functions. For a long time, IP6 has been recognized as a natural antioxidant. IP6 has received much attention for its role in cancer prevention and control of experimental tumor growth, progression, and metastasis.

IP6, a naturally polyphosphorylated carbohydrate, has been reported to have significant in vivo and in vitro anticancer activity against numerous tumours, such as colon, prostate, breast, liver, and rhabdomyosarcomas. IP6 had a dose-dependent cytotoxic effect on all of the evaluated cell lines, with accumulation in the G2M phase in two out of five cell lines tested. At the molecular level, cDNA microarray analysis after IP6 exposure showed an extensive downmodulation of genes involved in transcription and cell cycle regulation and a coherent upregulation of cell cycle inhibitors.

The viability of glioblastoma T98G cells decreased following treatment with increasing doses of IP6. Cells exposed to 0.25, 0.5, and 1 mM IP6 for 24 hours showed morphological and biochemical features of apoptosis. Western blotting indicated changes in expression of Bax and Bcl-2 proteins resulting in an increase in Bax:Bcl-2 ratio and upregulation of cytosolic levels of cytochrome c and Smac/Diablo, suggesting involvement.

In prostate carcinoma LNCaP cells, IP6 caused a dose- and time-dependent apoptotic death, a decrease in Bcl2 levels causing a strong increase in Bax versus Bcl2 ratio, as well as an inhibition of constitutively active AKT phosphorylation. These molecular alterations provide an insight into IP6-caused growth inhibition, G1 arrest, and apoptotic death of human prostate carcinoma cells. The results suggest that IP6 has promise and potential to be effective against prostate cancer.

Human Clinical Evidence

Clinical evidence in humans is limited but exists in the form of small pilot trials. A prospective, randomized, pilot clinical study was conducted to evaluate the beneficial effects of IP6 + inositol in breast cancer patients treated with adjuvant therapy. Patients with invasive ductal breast cancer for whom polychemotherapy was indicated were monitored in the period from 2005 to 2007. Fourteen patients in the same stage of ductal invasive breast cancer were involved in the study, divided into two randomized groups. One group was assigned to take IP6 + inositol while the other group received placebo. In both groups, the same laboratory parameters were monitored. When treatment was finished, all patients completed questionnaires QLQ C30 and QLQ-BR23 to determine quality of life. Patients receiving chemotherapy along with IP6 + inositol did not have cytopenia, or drops in leukocyte and platelet counts.

When IP6 plus inositol was given in combination with chemotherapy, side effects of chemotherapy (drop in leukocyte and platelet counts, nausea, vomiting, alopecia) were diminished and patients were able to perform their daily activities. Further controlled randomized clinical trials are necessary to confirm these observations.

Lab studies have shown anticancer effects, but clinical data are lacking for most cancer types. The effectiveness and safety of IP6 plus inositol need to be determined in Phase I and Phase II clinical trials in humans. The overall strength of evidence for anti-cancer effects of supplemental IP6 in humans is therefore preliminary: a handful of very small pilot studies and case reports, with no completed large-scale randomized controlled trials.

4.2 Cardiovascular Calcification and Vascular Disease

Preclinical Evidence

In rats, aggressive cardiovascular calcifications were induced by the administration of high doses of vitamin D. Rats injected with SNF472 (an intravenous formulation of InsP6) showed reductions of aortic and heart calcification by 60% and 70%, respectively.

Clinical Evidence

The most clinically developed evidence for IP6 pertains to its pharmaceutical formulation SNF472 and vascular calcification in patients with end-stage kidney disease. Perelló et al. (2018) enrolled both healthy and hemodialysis patients in the first-in-human, double-blind, randomized, placebo-controlled Phase I study to assess the safety, tolerability, and pharmacokinetics of SNF472. Inhibition of the induction of hydroxyapatite crystallization in plasma samples was demonstrable by SNF472.

The landmark Phase IIb clinical trial was the CaLIPSO study: In this Phase IIb study, 274 patients with end-stage kidney disease who underwent dialysis were randomized to SNF472 administered at two different doses (300 mg or 600 mg) or placebo (1:1:1) for 52 weeks. For the primary endpoint at 12 months, using data from the combined dose group, administration of SNF472 resulted in significant slowing of progression of coronary artery calcification (11%; 95% CI: 7% to 15% vs. 20%; 95% CI: 14% to 26%; p = 0.016). Secondary endpoints also showed slowing of progression of aortic valve calcification (14%; 95% CI: 5% to 24% vs. 98%; 95% CI: 77% to 123%; p < 0.001). Notwithstanding these promising data, larger studies are required to delineate the clinical efficacy and safety of this compound.

SNF472 has completed early-phase clinical trials with a favourable safety profile, and Phase 2 clinical trial data have shown attenuation of coronary artery and aortic valve calcification in patients receiving hemodialysis. It is critical to note that these results pertain to an intravenous pharmaceutical formulation; an intravenous form has been evaluated in preliminary studies to see whether it can slow progression of cardiovascular disease. However, no studies have been conducted on IP6 supplements for this use.

Regarding dietary phytate and cardiovascular outcomes, Sanchis et al. (2018) demonstrated in an in vitro and in vivo randomized crossover trial that consumption of InsP6 inhibits protein glycation in patients with type 2 diabetes mellitus. Advanced glycation end products (AGEs) and the receptor for advanced glycation end products (RAGE) play pivotal roles in vascular calcification in atherosclerosis. AGEs contribute to microvascular and macrovascular complications in type 2 diabetes mellitus, in chronic kidney disease, and in aging-related complications.

4.3 Kidney Stones (Renal Lithiasis)

The extraordinary capacity of phytate (myo-inositol hexaphosphate), a substance present in blood, urine, interstitial, and intracellular fluids, to inhibit crystallization of calcium salts (oxalate and phosphate) has been discussed. Its role in preventing calcium renal stone formation has been specifically presented. In vitro and in vivo experiments, as well as clinical studies, clearly demonstrate that phytate plays an important role as a crystallization inhibitor of calcium salts in biological fluids and represents a clear alternative in the treatment of calcium oxalate renal lithiasis.

IP6 was administered orally either as the pure sodium salt or in a diet to reduce hypercalciuria and to prevent formation of kidney stones, and no evidence of toxicity was reported. Oral or topical administration of phytate in vivo significantly decreases the development of pathological calcifications, although the details of the underlying mechanism are uncertain.

Despite these encouraging findings, Memorial Sloan Kettering Cancer Center notes that evidence is lacking to support the claim that IP6 supplements specifically treat kidney stones. The evidence base currently consists of observational data linking higher dietary phytate intake to lower kidney stone incidence, mechanistic studies, and small clinical experiments; no large randomized controlled trials on supplemental IP6 for this indication have been completed.

4.4 Bone Health

The adsorption of phytate to the crystal faces can inhibit hydroxyapatite dissolution and bone resorption, thereby playing a role in the treatment and prevention of bone mass loss. Since hydroxyapatite crystal growth within bone matrix is an essential process in bone formation, it is possible that IP6 intake may inhibit physiological mineralization and bone formation, although currently more published studies suggest that IP6 may contribute to bone health rather than inhibit bone formation. The overall evidence on bone health remains mixed, and the question of whether supplemental IP6 benefits or harms bone mineral density in humans has not been resolved by large clinical trials.

4.5 Cholesterol, Lipid Metabolism, and Diabetes

A potential hypocholesterolemic effect of IP6 may be very significant in the clinical management of hyperlipidemia and diabetes. Studies suggested that phytic acid and myo-inositol increase insulin sensitivity in adipocytes by increasing lipid storage capacity, improving glucose uptake, and inhibiting lipolysis. The synergistic effect of IP6 and inositol was observed not only in cancer but also in metabolic diseases. This combination has been beneficial in regulation of insulin secretion and was effective in the management of type 2 diabetes mellitus. These findings are largely from preclinical or small human studies and should be considered preliminary.

4.6 Platelet Activity and Cardiovascular Protection

IP6 inhibits agonist-induced platelet aggregation and efficiently protects myocardium from ischemic damage and reperfusion injury, both of which are important for the management of cardiovascular diseases. IP6 may also inhibit in vitro platelet activation with ADP, collagen, and thrombin by interacting with platelet cytoskeletal reorganization. Clinical evidence for antiplatelet effects of supplemental IP6 in humans is limited.

4.7 Immune Function

IP6 possesses other significant benefits for human health, such as the ability to enhance the immune system, prevent pathological calcification and kidney stone formation, lower elevated serum cholesterol, and reduce pathological platelet activity. Mechanistically, lower inositol phosphates can act as antioxidants by inhibiting iron-mediated oxidative reactions, enhancing immunity by increasing Natural Killer cell function and activity, and stimulating bacterial killing by neutrophils. Direct human clinical evidence for immune enhancement by supplemental IP6 is limited.

5. Body Systems Associated with Inositol Phosphate Activity

  • Oncology / Cell Biology: Antiproliferative, pro-apoptotic, and differentiation-inducing effects on multiple cancer cell lines (colon, breast, prostate, glioblastoma, leukemia, bladder) documented in vitro and in animal models; limited human pilot data.
  • Cardiovascular System: Inhibition of hydroxyapatite-mediated vascular and valvular calcification; antiplatelet activity; myocardial protection from ischemia-reperfusion injury in animal models; Phase IIb clinical trial evidence for the IV formulation SNF472.
  • Renal / Urological System: Crystallization inhibition of calcium oxalate and calcium phosphate; observational and mechanistic evidence for reduction of kidney stone formation.
  • Skeletal System: Inhibition of pathological calcium crystal growth; possible role in prevention of bone mass loss; complex relationship with physiological bone mineralization.
  • Metabolic / Endocrine System: Influence on insulin sensitivity, glucose uptake, and lipid metabolism; inhibition of advanced glycation end-product formation.
  • Immune System: Enhancement of NK cell activity and neutrophil-mediated bacterial killing; immunomodulatory effects described in animal and in vitro models.
  • Gastrointestinal System: Primary site of mineral chelation; interaction with digestive enzyme function; effects on nutrient bioavailability.
  • Antioxidant Defense: Iron chelation preventing Fenton-reaction-driven free radical generation; suppression of lipid peroxidation.

6. Dosage Forms and Dosages Reported in Studies

Dosages vary considerably depending on the route of administration and the clinical indication studied.

  • Dietary intake (habitual): The Mediterranean diet provides 1 g to 1.5 g of daily phytate as a calcium/magnesium salt. The European/American diet can supply a broad range of 0.2 g to 1.5 g of daily phytate, depending on consumption of legumes, nuts, and whole cereals.
  • Intravenous (pharmaceutical — SNF472, clinical trials): In the CaLIPSO Phase IIb study, patients were randomized to SNF472 administered at two different doses (300 mg or 600 mg) or placebo for 52 weeks.
  • In vitro cell studies: Colon cancer Caco-2 cells were exposed to InsP6 at concentrations of 1 mM, 2.5 mM, and 5 mM. T98G glioblastoma cells were exposed to 0.25, 0.5, and 1 mM IP6 for 24 hours.
  • Oral supplemental forms (supplement products): Capsule strengths typically range from 250 mg to 1,000 mg of IP6 per serving.
  • Case report (metastatic melanoma): A patient opted for combined inositol and IP6 (800 mg/220 mg) supplement (five tablets in the morning and five in the evening daily).

No standardized therapeutic dosage for supplemental oral IP6 has been established through large-scale clinical trials for any indication.

7. Safety Considerations and Interactions

7.1 Regulatory Safety Status

The FDA classifies phytin as Generally Recognized As Safe (GRAS). In humans, IP6 not only has almost no toxic effects, but it has many other beneficial health effects such as inhibition of kidney stone formation and reduction in risk of developing cardiovascular disease.

7.2 Mineral Absorption and Antinutrient Effects

IP6 is highly polar and poorly absorbed when given orally. When high oral doses are administered, IP6 has chelating properties in the gastrointestinal lumen, preventing the absorption of cations such as calcium, magnesium, and iron. This effect occurs primarily when phytate is supplied in large amounts with unbalanced diets, in which case the formation of insoluble compounds reduces the absorption of trace elements. However, consumption of phytate in moderate amounts with balanced diets does not reduce the bioavailability of these essential elements.

When phytate is consumed in large amounts, by itself and without being processed/cooked, it can reduce the absorption of some minerals. This has led to phytate being classified by some authors as an antinutrient. Nevertheless, this effect is only seen in laboratory conditions, and real-world data in humans do not demonstrate mineral deficiencies induced by phytate intake.

Early reports fueled concerns that high dietary phytate intake could contribute to mineral deficiencies, albeit without direct scientific evidence, particularly in populations lacking dietary diversity. However, lifetime animal experiments have demonstrated that IP6 does not have any negative effect on mineral bioavailability, and if there is any in humans, it is largely context-dependent.

7.3 Potential Concern: Bone Mineralization

Since hydroxy-apatite crystal growth within bone matrix is an essential process in bone formation, it is possible that IP6 intake may inhibit physiological mineralization and bone formation, although currently more published studies suggest that IP6 may contribute to bone health rather than inhibit bone formation. This theoretical concern applies particularly to high supplemental doses and warrants further investigation.

7.4 Drug and Supplement Interactions

When high oral doses are administered, IP6 has chelating properties in the gastrointestinal lumen, preventing the absorption of cations such as calcium, magnesium, and iron. This property creates a potential for interaction with mineral supplements and medications that depend on adequate mineral absorption. Taking IP6 at the same time as iron, zinc, calcium, or magnesium supplements could reduce absorption of those minerals.

IP6 inhibits agonist-induced platelet aggregation. This antiplatelet activity suggests a theoretical interaction risk when IP6 is combined with anticoagulant or antiplatelet medications, although direct human pharmacokinetic studies on such interactions have not been reported in the available literature.

Some authors have observed increased cadmium (Cd) retention due to phytate, others have suggested that Cd absorption is reduced by phytates, and still others have found no influence of phytate level on Cd retention. When the sodium salt of phytate is provided as a dietary supplement it either has no effect or increases Cd accumulation. This finding suggests that the form of IP6 administered (food-matrix-bound vs. isolated supplement) may have differential effects on heavy metal absorption.

7.5 Evidence Limitations and Gaps

Large-scale studies are needed to confirm anticancer effects. Larger studies are needed for chemotherapy-support applications. Although IP6 has a native protective effect on blood vessels, it has limited absorption via the gastrointestinal tract and poor oral bioavailability, limiting its clinical application. The gap between the robust preclinical evidence for IP6 and the limited clinical evidence in humans is a defining characteristic of the current research landscape. Phytate has shown promising results in the treatment and prevention of medical conditions in in vitro data, animal models, and in some human clinical trials. However, most human studies are small, non-blinded, or observational, and the translation of laboratory findings to clinical efficacy at supplemental oral doses has not been established for most proposed indications.

References

Health Conditions

Health conditions that Inositol phosphate may help support.

  • No conditions available.

Body Systems

Body systems that Inositol phosphate may help support.

  • No body systems available.
Join our newsletter

Stay informed. Stay healthy.

Get expert supplement tips, exclusive discounts, and product recommendations delivered to your inbox

Inositol phosphate | Vitabase